Hunan Er-Kang Pharmaceutical Co., Ltd (SHE:300267)
China · Delayed Price · Currency is CNY 3.020
+0.040 (1.34%)
Jul 29, 2026, 3:04 PM CST
SHE:300267 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 28, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
| 6,229 | 7,033 | 5,734 | 6,621 | 7,322 | 9,777 | |
Market Cap Growth | -30.41% | 22.66% | -13.40% | -9.58% | -25.11% | 12.59% |
Enterprise Value | 5,816 | 6,697 | 5,344 | 6,256 | 7,251 | 9,643 |
Last Close Price | 3.02 | 3.41 | 2.78 | 3.21 | 3.52 | 4.70 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 28, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | - | - | - | - | 159.37 | - |
Forward PE | - | 38.54 | 38.54 | 38.54 | 38.54 | 38.54 |
PS Ratio | 5.88 | 6.03 | 5.03 | 3.71 | 3.92 | 4.37 |
PB Ratio | 1.57 | 1.77 | 1.30 | 1.38 | 1.45 | 2.01 |
P/TBV Ratio | 1.68 | 1.89 | 1.41 | 1.49 | 1.58 | 2.22 |
P/FCF Ratio | 75.25 | 75.06 | - | - | 68.10 | - |
P/OCF Ratio | 24.73 | 27.30 | 34.40 | 44.61 | 26.06 | 105.49 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 28, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
EV/Sales Ratio | 5.49 | 5.75 | 4.69 | 3.51 | 3.88 | 4.31 |
EV/EBITDA Ratio | 47.59 | 48.05 | 52.75 | 386.29 | 45.89 | 234.66 |
EV/FCF Ratio | 70.27 | 71.47 | - | - | 67.43 | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 28, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Debt / Equity Ratio | 0.18 | 0.15 | 0.12 | 0.07 | 0.08 | 0.05 |
Debt / EBITDA Ratio | 5.87 | 4.03 | 4.75 | 16.27 | 2.43 | 5.41 |
Debt / FCF Ratio | 8.66 | 6.28 | - | - | 3.75 | - |
Net Debt / Equity Ratio | -0.09 | -0.10 | -0.07 | -0.08 | -0.09 | -0.10 |
Net Debt / EBITDA Ratio | -3.02 | -2.86 | -3.05 | -24.65 | -3.01 | -12.40 |
Net Debt / FCF Ratio | -4.23 | -4.26 | 10.70 | 4.45 | -4.42 | 1.99 |
Asset Turnover | 0.21 | 0.23 | 0.21 | 0.32 | 0.33 | 0.37 |
Inventory Turnover | 1.37 | 1.63 | 1.32 | 1.99 | 1.90 | 2.61 |
Quick Ratio | 1.39 | 1.49 | 1.45 | 1.56 | 1.53 | 2.10 |
Current Ratio | 2.09 | 2.23 | 2.43 | 2.87 | 2.88 | 3.90 |
Return on Equity (ROE) | -9.88% | -9.53% | -8.52% | -4.50% | 0.75% | -14.90% |
Return on Assets (ROA) | -0.67% | -0.43% | -1.06% | -2.02% | -0.12% | -1.56% |
Return on Invested Capital (ROIC) | -1.51% | -0.91% | -2.12% | -4.07% | -0.24% | -3.21% |
Return on Capital Employed (ROCE) | -1.30% | -0.90% | -2.00% | -3.80% | -0.20% | -3.10% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 28, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Earnings Yield | -6.34% | -5.40% | -6.51% | -2.95% | 0.63% | -8.09% |
FCF Yield | 1.33% | 1.33% | -0.50% | -1.36% | 1.47% | -2.63% |
Dividend Yield | - | - | - | - | 0.85% | - |
Payout Ratio | - | - | - | - | 10.29% | - |
Buyback Yield / Dilution | 0.15% | -0.01% | -0.01% | -0.11% | 0.11% | 0.04% |
Total Shareholder Return | 0.15% | -0.01% | -0.01% | -0.11% | 0.96% | 0.04% |